Gene transfer to the lung can be achieved via either the airway or the pulmonary vasculature. We evaluated gene transfer and expression by intravascular and endobronchial routes, using DNA complexed with G9 PAMAM dendrimer or naked plasmid DNA. Intravascular tail vein delivery of dendrimer-complexed pCF1CAT plasmid resulted in high levels of transgene expression in the lung at 12 and 24 hr, followed by a second peak of expression 3 to 5 days after administration. After intravenous administration of the complexes, CAT expression was never observed in organs other than the lung. There were only minimal levels of CAT protein expressed in the lung after intravenous administration of naked plasmid DNA. Repeated intravascular doses of the dendrimer-complexed plasmid, administered four times at 4-day intervals, maintained expression at 15-25% of peak concentrations achieved after the initial dose. Endobronchial delivery of naked pCF1CAT plasmid produced significant amounts of CAT protein in the lung. Comparison of intratracheal and intranasal routes resulted in similar expression levels of CAT in the lung and trachea. However, in juxtaposition to vascular delivery, intranasal delivery of dendrimer-complexed plasmid DNA gave lower levels of CAT expression than that observed with naked plasmid DNA. In situ localization of CAT enzymatic activity suggested that vascular administration seemed to achieve expression in the lung parenchyma, mainly within the alveoli, while endobronchial administration primarily targeted bronchial epithelium. Our results show that intravenou sly administered G9 dendrimer is an effective vector for pulmonary gene transfer and that transgene expression can be prolonged by repeated administration of dendrimer-complexed DNA. a 1 -antitrypsin (a 1 -AT) genes to the lung. Different carriers to deliver DNA, such as viruses or liposomes, have been found to be inefficient or inflammator y in human subjects in vivo, highlighting the need to search for better gene transfer system s. The present study investigates the ability of PAMAM dendritic polymers (dendrimers) to augment plasmid DNA gene transfer in vivo and evaluates the targeting of the lung by alternative routes of administration. Dendrimer-complexed plasmid DNA delivered via the vasculature system increased transgene expression 20-40 times over DNA administered alone and appeared to target mainly the alveoli in the peripheral lung (possibly type II pneumocytes). Naked plasmid DNA was efficiently expressed when delivered either intranasally or intratracheally, and the expressed protein was localized primarily in the ciliated epithelium of the lung and trachea. Repeated intravascular administration of dendrimer-complexed DNA resulted in gene expression for up to 16 days with CAT protein concentration reaching 15-25% of the peak values observed after a single administration.
INTRODUCTION P
inherited pulmonary diseases such as cystic fibrosis (CF) and a 1 -antitrypsin deficiency (a 1 -AT) (Crystal et al., 1989; Kerem et al., 1989; Collins, 1992) and for lung cancer (Taya et al., 1984; Lee et al., 1995) are being elucidated. There are no effective therapies for these or other pulmonary disorders such as malignant mesothelioma, a unique localized intrathoracic malignancy without a major metastatic component (Lee et al., 1986) . Chronic inflammatory lung diseases such as idiopathic pulmonary fibrosis (IPF) and asthma are localized to the lung, but lack adequate treatments (Carrington et al., 1978; TurnerWarwick et al., 1980; Demoly et al., 1997) . Advances in understanding the physiologic basis of these diseases indicate that therapeutic benefits may result from the expression of cytokines, surfactants, antioxidant enzym es, or mucoproteins (McElvaney et al., 1991; Christman et al., 1993; Conary et al., 1994; Piguet and Vesin, 1994; Wang et al., 1994; Rogy et al., 1995) .
The lung is accessible either directly through the airway or through the vascular system. This offers the possibility to achieve gene transfection to the endothelial cells, as well as to the lung parenchyma (Zhu et al., 1993) . However, the utility of endobronchial delivery may be limited by the need for special formulations or by mucociliary clearance of the therapeutic (Clarke and Pavia, 1991) . Despite this, the respiratory epithelium has been a primary target for CF transmembran e conductance regulator (CFTR) gene therapy for a number of years (Trapnell et al., 1991; Rosenfeld et al., 1992; Hyde et al., 1993; Wagner et al., 1995) . In animal models, gene transfer was achieved with a variety of endobronchially administered gene transfer vectors including viruses, lipids, or naked plasmid DNA. The advantages and safety issues associated with these approaches have been well characterized and described (Brigham et al., 1989; Hazinski et al., 1991; Rosenfeld et al., 1991; Stribling et al., 1992; Alton et al., 1993; Mastrangeli et al., 1993; Canonico et al., 1994; Yei et al., 1994; Zabner et al., 1994; Tsan et al., 1995) . Several attem pts to modify viral vectors to prevent immune response that causes systemic toxicity (Mack et al., 1997) , and to improve the formulations of cationic liposomes for in vivo transfection (Schughart et al., 1999) , have not been entirely successful. Thus, the further progress of human gene therapy depends on the developm ent of safe and more efficient vector systems.
We have previously studied the characteristics and the efficiency of polyamidoamin e (PAMAM) dendritic polymers (dendrimers) as vectors for gene transfer both in vitro (Bielinska et al., , 1997 Kukowska-La tallo et al., 1996 and in vivo in murine cardiac transplants (Qin et al., 1998) . Furthermore, we have reported that naked plasmid DNA can transfect mouse airway epithelium in vivo, and we have established that surfactant can be a major factor inhibiting this process (Raczka et al., 1998) . The present work compares transgene expression from chloramphenicol acetyltransferase (CAT) expression plasmid achieved in vivo in the mouse lung after either intravenous or endobronchial administration. The expression of naked plasmid is compared with that observed when plasmid DNA is complexed with dendritic polymer as a nonviral vector. The results dem onstrate that each delivery route requires different vectors to achieve optimal transgene expression, that each approach appears to target different cells within the lung, and that an extended expression of a transgene can be achieved with intravascular delivery of dendrim er-complexed DNA.
MATERIALS AND METHODS

Plasmid DNA
The pCF1CAT plasmid used in this study was provided by R. Scheule and S. Cheng (Genzyme, Framingham, MA) . The construction and optimization of this plasm id have been previously described (Lee et al., 1996; Yew et al., 1997) . As a control for both in situ detection and biochemical evaluation of transfection, the previously described plasmid pCF1Luc expressing the luciferase gene was used (Raczka et al., 1998) . Plasmid DNA was purified through the double cesium chloride gradient and then dialyzed. Preparations were assayed for endotoxin level, protein contamination, and Escherichia coli DNA content in the Human Applications Laboratory and Vector Core Laboratory at the University of Michigan (Ann Arbor, MI). In preliminary studies, endotoxin contamination of plasm id preparations was correlated with decreased chloramphenico l acetyltransferase (CAT) expression and toxicity when the DNA was com plexed with dendrimer and administered intravascularly. Consequently, we have used plasmid preparations with endotoxin concentrations less than 1 EU/mg of DNA for the experiments presented in this report (Table 1) .
Polymer vector
Polyamidoam ine (PAMAM) dendrimers, well-defined synthetic polymers, have been previously described (Kukow skaLatallo et al., 1996) . Dendrimers form complexes with DNA through electrostatic interactions between negatively charged phosphate groups in the nucleic acid and positively charged amino groups on the polymer. In the current study, we have used a ninth generation of dendrimer (G9) with an ethylenediamine initiator core (EDA). This polym er is a spherical molecule with a diameter of approximately 114 Å, a molar mass of 467 kDa, and 2048 surface primary amino groups per molecule. The choice of the polymer was based on our prior in vitro and in vivo transfection studies (Kukowska-L atallo et al., 1996 (Kukowska-L atallo et al., , 1999 Bielinska et al., 1997; Qin et al., 1998) and preliminary toxicity studies.
Polymer-DNA complex formation
In the current work, plasmid DNA not complexed with dendrimer and delivered in saline solution or in water is referred to as naked plasmid DNA. Complexes of dendrimer and plasmid DNA were formed by mixing in physiological saline (0.9% NaCl in sterile water) for intravascular delivery or in water for intranasal delivery. The G9 EDA dendrimer has been used at a charge ratio of polymer to DNA of 5 for intravenous administration and of 1, 5, or 10 for endobronchial administration.
Animals
Female BALB/c mice, 35-45 days old and weighing 18-20 g (Charles River Laboratories, Wilmington, MA) were used in all experiments. The experiments were approved and complied with the guidelines of the University of Michigan Committee on the Use and Care of Animals.
Intravascular and endobronchi al delivery studies
The time course of CAT expression in the lung was examined after intravenous adm inistration of dendrimer (650 m g)-com plexed plasmid DNA (200 m g) or naked plasmid DNA (200 m g) at 6 and 12 hr, and 1, 2, 3, 4, 5, and 7 days after delivery. The control groups of animals received either pCF1LucDNA (200 m g), naked or complexed with dendrimer, or physiological saline (200 m l), and were killed after 12 hr or 4 days postdelivery. In experiments in which one to four repeated doses were administered, the anim als were killed 4 days after the last dose. Additional groups of mice were killed 12 hr after the first and fourth administration. Transfection was also evaluated in the heart, kidneys, pancreas, liver, spleen, and lymph nodes 12 hr and 4 days after the intravenous administration of dendrimercom plexed DNA. Intravascular delivery was accomplished by immobilizing mice in a small Plexiglas box and injecting samples via the tail vein. The DNA-dendrimer or DNA solutions were delivered in a 200-m l volume of physiological saline, using a 27-gauge needle attached to a 1-ml syringe. Groups of mice receiving repeated intravascular administrations were injected 4 days apart on one to four occasions for each group, with lung tissue harvest performed 4 days after the last delivery. Tissue was also obtained from a group of animals 12 hr after the first and fourth administration.
For endobronchial delivery, naked plasmid DNA (100 m g) or complexed with dendrimer (65-650 m g) was prepared in 100 m l of sterile water. The different dendrimer-DNA charge ratios, as well as possible differences between intranasal and intratracheal adm inistration and possible differences in transfection betw een the trachea and the lung tissues, were evaluated. Mice administered with either pCF1Luc (100 m g) or physiological saline (100 m l) were included in each type of experiment. Intranasal delivery was perform ed on mice anesthetized with methoxyflurane (Metofane; Mallinckrodt Veterinary, Mundelein, IL) inhalation. They were held supine with the head slightly elevated and the mouth closed. A 100-m l volume of transfection mixture was delivered quickly from a 200-m l micropipette tip, directly through the nasal orifices during respiration. Intratracheal instillation was perform ed by a modification of the method of Otto-Verberne et al. (1992) . Mice under methoxyflurane anesthesia were held in an upright position by suspending them on their front teeth. The light tip of a fiberoptic light was placed against the skin of the animal at throat level. After the tongue was extended from the mouth, the trachea, visible as a white ring, was quickly intubated with a 20-gauge venous catheter attached to a 1-ml syringe. Transfection solution (100 m l) was injected through the glottis into the trachea and the catheter was rem oved. The animals then remained in a vertical position for a few seconds after the instillation.
Harvesting and processing of tissue
At different time points from 6 hr to 16 days after the first plasm id delivery, during deep anesthesia with Metofane, the abdom inal cavity of each mouse was opened and the mice were bled out through cutting the abdom inal aorta and the vena cava. The chest was then opened and the pulmonary vascular bed was flushed by slowly injecting 3 ml of phosphate-buffere d saline (PBS) into the right ventricle of the heart. The trachea and the lungs were excised and rem oved en bloc, then weighed and washed in PBS. An appropriate cold lysis buffer was added at 1 m l/mg of tissue (lysis buffer for CAT enzyme-linked immunosorbent assay [ELISA] proprietary to Boehringer Mannheim [Indianapolis, IN] was supplemented with aprotinin [5 m g/ml], 5 mM 1,4-dithiothreitho l [DTT, Cleland' s reagent], and 0.2 mM phenylmethylsul fonyl fluoride [PMSF] ). The tissue was hom ogenized with a tissue hom ogenizer (Biospec Products, Bartlesville, OK) for 30 sec, and then frozen in liquid nitrogen and stored at 2 80°C until assayed. For assessment of distribution of expression to organs other than the lung, tissue was harvested from the heart, kidneys, pancreas, liver, spleen, and lymph nodes.
CAT ELISA
To quantify CAT expression tissue homogenate lysate was centrifuged at 12,000 3 g for 10-15 min at 4°C. The amount of CAT protein was measured in 50 m l of the supernatant by an ELISA (Boehringer Mannheim). It was adjusted for the concentration of the total soluble protein present in the sample as measured by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL) with bovine serum albumin as the standard.
Histochemical staining of CAT activity
To obtain cryostat sections, lung tissue was prepared by washing the pulmonary vascular bed with PBS. This step was followed by closure with a suture of the left main bronchus. The right lung was infused through the trachea with embedding 
Statistical analysis
Statview 4.5 (Abacus Concepts, Berkeley, CA) was used for the statistical analysis. At least five mice were used for each data point. All assays were performed in triplicate on individual lung homogenates and presented as averages. Data were com pared by one-way analysis of variance (ANOVA). All values were expressed as means 6 SEM, and p values less than 0.05 were considered significant.
RESULTS
CAT expression after intravascular delivery
The highest levels of intrapulmonic transgene expression were observed when pCF1CAT DNA (200 m g) complexed with dendrimer (650 m g of G9 EDA) was administered intravascularly in physiological saline (200 m l) (Fig. 1 ). Significant amounts of CAT protein (14.8 6 3.1 ng/g soluble protein) were already found in lung tissue at 6 hr, with the highest level at 12 hr after administration (93.4 6 10.4 ng/g). CAT concentrations then declined 1 day (66.1 6 9.7 ng/g) and 2 days (13.5 6 2.4 ng/g) after injection of the complex. A second wave of CAT expression began on day 3 (22.6 6 5.4 ng/g), peaked on day 4 (34.1 6 3.7 ng/g), and decreased thereafter on days 5 and 7 postadministrati on (15.7 6 1.7 and 3.8 6 0.6 ng/g, respectively; Fig. 1 ). Intravascular delivery of naked plasmid DNA yielded low levels of CAT protein (0.6-3.5 ng/g) 12 hr to 7 days after administration (Fig. 1) . No CAT protein was detected in the lungs of control mice treated with either naked pCF1Luc DNA or physiological saline (data not shown).
There appeared to be no cumulative effect from repeated doses of dendrim er-complexed DNA (up to four doses at 4-day intervals), as the level of CAT protein in the lung never exceeded that observed with a single administration. As shown in Fig. 2 , the amount of expressed CAT protein, measured 12 hr and 4 days after the fourth dose, was at 15-25% of the levels achieved after the initial dose. Naked plasmid DNA, administered repeatedly at 4-day intervals, was expressed at low levels (under 4% of the maxim al expression achieved with dendrimercom plexed DNA) throughout the 16-day period of the study (data not shown). Expression after intravascular delivery of a single dose of dendrimer-com plexed DNA (650 m g of G9 EDA with 200 m g of pCF1CAT) monitored at 12 hr and 4 days was localized exclusively in the lung and not in the spleen, heart, liver, pancreas, kidneys, and lymph nodes (data not shown). Mice injected with naked plasmid DNA had no significant CAT activity in any of the organs tested (data not shown).
Expression of CAT after endobronchi al delivery
In contrast to intravascular delivery, endobronchial administration of naked pCF1CAT plasmid produced significant amounts of CAT protein (15-20 ng/g soluble protein) after intranasal delivery of 50 or 100 m g of DNA in 100 m l of sterile water (Table 2) . Maximum CAT expression (17. Compared with the expression level of naked DNA, CAT expression was increased at 6 and 12 hr, and at days 1, 2, 3, 4, and 5 after delivery, with the highest level at 12 hr and a second peak at day 4, and the lowest level at day 7. The values are the means 6 SEM of 6, 7, 7, 5, 6, 7, 7, and 7 mice for G9 EDA-DNA complexes, respectively. The values for mice that received naked plasmid DNA are averages from two mice, except for the value at 12 hr, where four mice were used. mid and did not increase when larger amounts of DNA (100 m g) were used ( Table 2) . Delivery of dendrim er G9 EDA-complexed plasmid DNA through the same route gave lower values of CAT expression than did naked DNA (Table 2) . Moreover, increases of up to 10-fold in the amount of dendrimer in the complex (increasing the charge ratio of dendrim er to DNA from 1 to 10) further reduced the level of CAT expression ( Table 2 ). Delivery of naked plasmid DNA, either intranasally or through an intratracheal catheter, did not yield significantly different levels of CAT expression in either lung or trachea tissues (Fig. 3) .
Comparison of intranasal delivery of naked plasmid DNA (100 m g of pCF1CAT DNA) with intravascular delivery of dendrimer-comple xed DNA (650 m g of G9 EDA with 200 m g of pCF1CAT DNA) demonstrated that threefold higher CAT expression could be achieved from the intravenous route (p , 0.01) (Fig. 4) .
Histopatholo gy and localization of expressed CAT protein
Histopathology did not reveal any changes, hem orrhage, or treatment-related damage to the lung. In particular, inflammation, neutrophils, or frank pneumonitis was not observed. Hematoxylin-and eosin (H&E)-staine d histologic sections showed the presence of dendrim er-DNA complexes in lung parenchym a. Large DNA-dendrimer complexes observed on H&E slides by visual microscopy were found not to be associated with CAT expression, detected by CAT staining of a slide containing the consecutive tissue section.
CAT protein was detected in situ in the right lung by the histochemical staining technique described in Materials and Methods. Preliminary studies showed evidence of CAT protein enzym atic activity 4 days after intravenous delivery of polymer-comp lexed DNA (650 m g of G9 EDA with 200 m g of pCF1CAT). In situ localization of the CAT protein in lung revealed uniform distribution in the alveolar epithelium ( Fig. 5A and B). Control animals received either dendrimer-com plexed pCF1Luc DNA (200 m g) at the same charge ratio (Fig. 5D) or saline (Fig. 5E) . Intranasal delivery of 100 m g of naked pCF1CAT DNA resulted in localized expression primarily in the ciliated epithelium of the respiratory bronchioles and occasionally in the alveolar epithelium (Fig. 5C ). The expression of CAT protein in the contralateral lung of each mouse, evaluated by ELISA, reflected the degree of staining observed with the in situ analysis (Fig. 5F ). fection systems are inappropriate to use in the human lung (Yang et al., 1994; Worgall et al., 1997; Zabner et al., 1997; Xiao et al., 1999) . Modifications may improve viral vectors; how ever, prudence suggests examining nonviral alternatives, from naked plasmid DNA to complex synthetic assemblies. Although these systems have uniformly lower levels of in vivo expression when compared with the most efficient viral vectors, it has been suggested that certain therapeutic applications of pulmonary gene therapy might require only low levels of expression obtained with naked DNA. For exam ple, in cystic fibrosis there is evidence, both in vitro (Rich et al.,1990; Johnson et al., 1992 Johnson et al., , 1995 and in vivo (Hyde et al., 1993; Zabner et al., 1993) , that low levels of CFTR expression could reestablish physiological ion transport. Thus, some form of enhanced transfer of plasmid DNA may be a viable therapeutic approach for pulmonary disorders, such as antiinflamm atory gene therapy of asthma or pulmonary fibrosis (Piguet and Vesin, 1994; Demoly et al., 1997) .
DISCUSSION
We were interested in evaluating gene expression in the lung from an efficient expression plasm id delivered either as naked DNA or complexed with cationic dendritic polymer, using endobronchial or intravascular delivery route. The in vivo results presented in this study demonstrate that the most effective synthetic vector to deliver DNA to the lung varies according to the FIG. 3 . Expression of CAT after intratracheal and intranasal delivery of naked pCF1CAT plasm id DNA (100 m g) in lung and trachea homogenates 5 days after intratracheal or intranasal delivery. The values are the means 6 SEM from eight mice.
FIG. 4.
Comparison of levels of CAT expression 4 days after endobronchial (left) or intravenous (right) delivery of G9 EDA complexed with pCF1CAT DNA (charge ratio of 5) or of naked plasm id DNA. Four sets represent the means 6 SEM of 3, 11, 14, and 4 mice. route of administration. Naked plasmid DNA achieved efficient expression when delivered to the respiratory epithelium by either intratracheal or intranasal administration, confirming our previous results (Raczka et al., 1998) . In contrast, naked DNA adm inistered intravenously achieved minimal expression in the lung. Intravascular administration achieved significant expression in the lung only when the plasmid was complexed with dendritic polymer. Interestingly, intravenous delivery of the dendrimer-DNA com plexes achieved higher CAT protein expression in the lung than did endobronchial delivery of naked plasm id DNA. Neither technique resulted in expression outside the lung, nor appeared to cause acute toxicity. However, several unique features were observed with the intravenous administration of the dendrimer-DNA complex. Transgene expression after intravascular delivery of the complex has two distinct phases. An initial peak is observed at 12 hr, with a second peak at 4 days. The duration of expression after a single intravenous administration was similar to what was observed previously for intrabronchial administration of naked DNA (Raczka et al., 1998) , but this expression could be maintained for longer periods of time by repeated administration. In contrast, neither naked DNA delivered intravenously nor dendrimer-DNA com plex administered intrabronchially could achieve significant levels of transgene expression. This suggests that expression efficiency of different vector systems is modified by the route of administration. The transient decrease in expression observed on days 1 and 2 after intravenous administration of the polymer-DNA complex is interesting to evaluate. As reported previously for clearance mechanisms of adenoviral vectors after intravenous administration (Worgall et al., 1997) and for retroviral gene transfer to airway epithelia (McCray et al., 1997) , there is likely an innate immune system of the lung that eliminates a vector or vector-expressing cells. It is also possible that the observed slow decline at the end of the 7-day time course is the result of the development of a specific immune response to either the polymer, the DNA, or CAT protein. However, several points argue against this hypothesis. First, we have detected no antibody response to the CAT protein or the dendrimer of the dendrimer-DNA complex in these animals 16 and 72 days after repeated administration (our unpublished data). While we found no humoral response even to CAT protein, it is possible that a cellular response to this or the complex caused the decreased expression at 7 days. The absence of inflammation or injury in the lung makes this less likely. In addition, the repeated administration of the dendrimer-DNA com plex maintained expression at 20-30% of peak levels, which would not occur in the presence of neutralizing immunity (Rivera et al., 1999) . Finally, an immune response does not explain the second peak of expression observed 4 days postadministratio n. This pattern of expression could result from delayed transfection of different types of cells or a secondary release of DNA from dendrimer-DNA com plexes. Both of these possibilities deserve further evaluation, as short-term transgene expression with different organ localization has been reported after liposomemediated intravascular delivery of plasmid DNA (Zhu et al., 1993) . Also, further identification of time-dependent differential localization of CAT protein may help in interpreting this unusual time course of expression.
In our study the CAT transgene was exclusively localized in the lung as compared with other tissues. We have documented that the intravenous delivery employed resulted in expression prolonged for 16 days, and in a localization pattern different from that observed with endobronchially administered naked plasm id DNA. In particular, this approach yielded uniform expression of CAT protein in the alveolar pneum ocytes in the periphery of the lung. The particular cell transfected in this area is difficult to assess since there are no ultrastructural characteristics that could differentiate between type I and type II alveolar pneum ocytes. However, transfection with naked DNA or vectors other than lentivirus requires mitotic activity (Naldini et al., 1996; Robbins and Ghivizzani, 1998; Mortimer et al., 1999) . The alveolar type II pneumocyte is a dividing and differentiating cell that serves as a progenitor for alveolar type I pneumocyte (Bowden, 1981) . Moreover, considering the location of expression, close to the alveolar septum where type I pneumocytes constitute only 7% of the alveolar septum, the type II pneumocyte seem s a better candidate than the type I pneumocyte (Fig. 5) .
Why administration of these complexes to the tail vein of the mice would result in this pattern of localized lung expression is not clear, especially since expression was not observed in any other organs (data not shown). It is possible that the complexed DNA (with a net positive charge) was entrapped in the circulatory system of the lung, which represents the first microvascular bed encountered after the tail vein adm inistration. Complexing DNA with an excess of positively charged dendrimer condenses the DNA and forms complexes ranging from 10 nm to 1 m m in diameter (Kukowska-L atallo et al., 1996) . It is possible that the size of these complexes will lead to passive deposition in the vascular bed. DNA in this complex is protected from nuclease activity while transcriptionally active in vitro (Bielinska et al., 1997) . Thus, this approach may aid intravascular transfection by protecting the DNA from nuclease activity before it deposits in the lung. It is also apparent that the com plexes had to transverse the vascular endothelium to transfect the alveolar epithelium . The mechanism of this process is of interest as it may provide insights into intravascular gene delivery in other organs. Ours is the first report describing prolonged (up to 16 days) transgene expression after repeated administrations in this pattern in the lung, which may within this time period have therapeutic relevance in, for example, antiinflammatory therapy (Dow et al., 1999) .
In contrast, the lung transgene expression we observed with endobronchial administration of naked DNA is consistent with most reports on the subject (Tsan et al., 1995; Wheeler et al., 1996; Raczka et al., 1998) . Our findings support the ability of naked plasmid DNA to transfect the ciliated epithelium of respiratory bronchioles and the trachea. In contrast, endobronchially administered adenovirus transfects essentially only the alveolar space (Rosenfeld et al., 1991) . The lower levels of expression after endobronchial delivery of the DNA-dendrimer com plexes as compared with naked plasmid DNA ( Table 2) are likely due to preferential clearance of com plexes by the mucociliary system before transfection could occur (Clarke and Pavia, 1991) . The inhibition of gene transfer by DNA-dendrimer complexes may be mediated by alveolar macrophages, which were reported to represent a barrier to retroviral gene transfer to pulmonary epithelia (McCray et al., 1997) or may result from inefficient endocytosis by the epithelial cells as com pared with naked plasmid DNA.
It is difficult to directly compare our data with the expression and tissue distribution reported by others since previously the expression was measured as an enzymatic acetylation activity of CAT. If the amount of acetylated product accurately reflects the amount of enzyme present, then the expression levels of CAT presented in our study should be 20 to 200 times higher than those reported by Meyer et al. (1995) . Only the levels of transfection reported in elegant work from the Genzyme group, using the most efficient nonviral system (cationic lipids), are twofold higher than our results, although experimental conditions and methods may account for at least part of this difference (Yew et al., 1997) . However, the lack of an inflammatory response to our dendrimer vector and the high level of organ specificity observed with DNA-dendrimer complex transfection make our results unique.
In conclusion, expression of DNA transgene in the mouse lung can be achieved either after endobronchial or intravenous adm inistration of plasmid DNA. The utility of com plexing DNA with a carrier (dendritic polym er) varies with the route of administration. Moreover, significant levels of transgene expression can be maintained for at least 16 days without inflammation by repeated intravenous doses of dendrimer-DNA com plexes. Consequently, intravenously adm inistered G9 dendrimer-DNA complexes are a potentially useful, nonviral vector system for in vivo gene transfer to the alveolar epithelium .
